GET DAILY SIGNALSReposiTrak (TRAK): Can Shares Recover to the $16 Analyst Target?
Key Takeaways
- The central target is $16.00, but it is a single analyst's price target — from Maxim Group's Tom Forte — not a multi-analyst consensus, because TRAK currently has effectively one active published target.
- The latest verified price is about $7.12, meaning shares would need to rise roughly 125% to reach $16, a very large move.
- The 52-week range is approximately $6.61 to $15.44, so $16 sits just above the prior 52-week high — a level the stock has touched before.
- The strongest supporting factor is the U.S. Food and Drug Administration's food traceability rule (FSMA Section 204), which is driving demand for ReposiTrak's traceability network.
- The biggest risks include a delayed FDA enforcement timeline, a fourth-quarter revenue decline, slowing growth, and very thin analyst coverage.
- You can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- To see how AI identifies changing trends across the market, explore Trending AI Robots.
Understanding the Lone $16 Price Target
ReposiTrak, Inc. (TRAK), the Utah-based software-as-a-service provider behind the ReposiTrak Traceability Network and food-supply-chain compliance platform, has fallen sharply from its 52-week high and now trades near its recent lows. With the stock recently changing hands around $7.12, the question for investors is whether shares can climb back toward the $16 level that remains the lone price target on Wall Street. The answer is not a simple yes or no: the $16 objective reflects a single analyst's view, and the required move is very large.
Unlike widely covered mega-caps, TRAK has very limited sell-side coverage. Aggregators such as TipRanks and MarketBeat currently show roughly one active analyst rating on the stock. That single view comes from Maxim Group analyst Tom Forte, who reiterated a Buy rating and a $16.00 price target in May 2026 and again in September 2026. Because only one credible, current, attributable target exists, there is no meaningful multi-analyst consensus to average; accordingly, the $16 figure here is presented as a single-analyst objective drawn from public discussion, not an analyst consensus.
For context, historical coverage shows a wider range of past views. Forte previously maintained an $11 target while at D.A. Davidson, and a dated data source lists an older $24 average. These are not current and are noted only to illustrate how thin and shifting TRAK's coverage has been. The relevant point is that the lone current target — $16 — represents a return to just above the stock's prior 52-week high, making it an ambitious but not arbitrary reference point. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
ReposiTrak recently closed near $7.12, down sharply from its 52-week high around $15.44 and not far above its 52-week low near $6.61. Reaching $16 would require roughly a 125% advance — a very large move by any measure, and one that would effectively require the stock to recover all of its recent decline and then set new highs.
Fundamentally, ReposiTrak is a small, profitable SaaS (software-as-a-service) business. Fiscal 2026 revenue grew 3% to about $23.3 million, with recurring revenue up 4%, while net income reached roughly $7.4 million and EPS (earnings per share) about $0.39. The balance sheet is notably clean, with around $27 million in cash and minimal debt, and the company pays a modest dividend. The path to $16 would most likely depend on a reacceleration in traceability revenue as the FDA's compliance deadlines approach, rather than on any single quarter.
Factors That Could Support a Move Higher
- Regulatory demand. The FDA's Food Safety Modernization Act traceability rule requires enhanced recordkeeping for designated foods, positioning ReposiTrak's traceability network as a compliance solution for retailers and suppliers.
- Recurring revenue. The company has been shifting its mix toward predictable subscription revenue, which supports valuation multiples.
- Financial strength. Strong cash reserves, minimal debt, and consistent profitability give the company flexibility to invest and return capital.
- New initiatives. Management has cited "touchless retailing" and its SPAR relationship as potential growth drivers expected to contribute more meaningfully in 2027 and beyond.
Risks That Could Keep the Target Out of Reach
- Delayed enforcement. The FDA pushed its original January 2026 compliance date back to July 2028, and management linked a fourth-quarter revenue decline partly to an earlier rush of activity before the original deadline.
- Slowing growth. Fiscal 2026 revenue rose only 3%, and fourth-quarter revenue declined year over year, weighing on sentiment.
- Small-cap and coverage risk. A roughly $130 million market capitalization and minimal analyst coverage can amplify volatility and limit institutional support.
- Valuation reset. Even after the decline, the stock trades at a meaningful P/E (price-to-earnings) multiple, and further multiple compression remains possible.
Technical Levels and Market Structure
The chart shows a stock that broke down from levels near $15 to the low single digits. The $16 target sits just above the 52-week high near $15.44, making that area a key overhead resistance zone and prior high. On the downside, the 52-week low near $6.61 is an important support level; a sustained close below it would undermine the bullish case. Between these extremes, round-number levels such as $10 and $12 are likely to act as psychological resistance zones on any recovery. From what I see, these levels deserve close attention on any rebound attempt.
Time Horizon and What Investors Should Monitor
A $16 price target of this kind generally reflects a roughly 12-month research horizon, though with a single analyst the timeframe is inherently less precise. Key items to watch include the company's next earnings report, management's commentary on traceability demand and the FDA timeline, the ramp of touchless retailing, any analyst revisions, and progress on the company's stated goal of redeeming remaining preferred shares. Regulatory milestones around the 2028 FDA deadline will be the most important long-term catalyst. I'm watching this closely for signs of renewed momentum.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a small-cap name like TRAK with limited analyst coverage, these signals can offer an additional, data-driven way to track shifting momentum and identify turning points as they emerge. Traders can use the tool to discover opportunities, monitor existing positions, and spot changing trends more efficiently.
Final Assessment
Can ReposiTrak (TRAK) stock reach $16? The target is real but rests on a single analyst's view rather than a broad consensus, and it demands a very large advance of roughly 125% from the current price near $7.12. The supporting case is anchored in regulatory tailwinds from food traceability requirements, a clean balance sheet, and recurring revenue, while the principal obstacles are a delayed FDA enforcement timeline, decelerating revenue growth, and thin coverage. For now, $16 represents a plausible return to the prior 52-week high rather than a near-term expectation, and investors should watch earnings, regulatory milestones, and any new analyst coverage for signals on whether that recovery thesis is gaining traction.
Exploring Tickeron AI Tools for Research
In my own work, I often turn to Tickeron’s AI Daily Buy/Sell Signals to supplement traditional analysis, especially for names with thinner coverage. The platform helps flag potential shifts in momentum across a wide range of stocks, which can be useful when evaluating recovery scenarios like the one for TRAK. It provides a practical layer of data-driven insight without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRAK's Indicator enters downward trend
The Aroon Indicator for TRAK entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator formed such a pattern. In 184 of the 222 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRAK as a result. In 62 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRAK's RSI Indicator exited the oversold zone, 20 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 59 cases where TRAK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for TRAK just turned positive on November 09, 2026. Looking at past instances where TRAK's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
TRAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.349) is normal, around the industry mean (-1.906). P/E Ratio (16.488) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (2.824). Dividend Yield (0.012) settles around the average of (0.069) among similar stocks. P/S Ratio (6.693) is also within normal values, averaging (70.383).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TRAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary software products
Industry PackagedSoftware
Advertisement